Market news

STAAR Surgical (STAA) stock gains as Stifel upgrades the company to Buy, citing a compelling entry point and H2 2026 sales upside—especially in China. Read more here.

Stifel Financial (SF) said Thursday that client assets at the end of August were $587.62 billion, up

Detailed price information for Microsoft Corp (MSFT-Q) from The Globe and Mail including charting and trades.

Several growth engines are beginning to line up again

Stifel also sees pluggable optics as an underappreciated volume driver across AI networks

CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinic

The investment firm upgraded the tech giant to buy from hold.

Nike will report Q1 FY27 results Oct. 1. Stifel maintains Hold, cuts target to $40, citing promotional pressure and weak product demand.

Motley Fool Press Release.

Stifel expects greater promotional activity in Western markets and a more challenging year-over-year gross margin comparison in the fiscal fourth quarter.